NVO Stock: Price, Earnings History and SEC Filings
Novo Nordisk A/S (NVO) last traded at $40.00, up 2.20% on the latest session and up 5.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.96 against an analyst estimate of $0.82, a beat of 17.1%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NVO earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $0.96 | $0.82 | +17.07% |
| Mar 2026 | May 6, 2026 | $1.04 | $0.87 | +19.54% |
| Dec 2025 | Feb 4, 2026 | $1.00 | $0.90 | +11.11% |
| Sep 2025 | Nov 5, 2025 | $1.02 | $0.77 | +32.47% |
NVO beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for NVO
Insider filing activity
NVO insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
NVO news
- Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?Nov 1, 2026 · fool.com
- Eli Lilly Rallies 11% in a Week as Q3 Sales Jump 39%, “Exceeding Our Prior Expectations”Oct 31, 2026 · tikr.com
- Eli Lilly Soars 11% in a Week on a $5.5 Billion Guidance Raise: “Beating on the Up”Oct 31, 2026 · tikr.com
- Can Novo Nordisk (NYSE:NVO) Trade Below Fair Value On Earnings?Oct 31, 2026 · finance.yahoo.com
- Novo Nordisk (NYSE:NVO) Could Be 61% Undervalued Following Rising GLP 1 CompetitionOct 30, 2026 · finance.yahoo.com
- Eli Lilly’s Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss DrugsOct 30, 2026 · 247wallst.com
- Novo Nordisk (NVO) Sets New 2030 Goals As GLP 1 Competition BuildsOct 30, 2026 · finance.yahoo.com
- Agios Sinks 18% as FDA Delays Sickle Cell Drug Decision to 2027 Despite Being “Launch-Ready”Oct 30, 2026 · tikr.com
About Novo Nordisk A/S
Novo Nordisk A/S (NVO) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.